Study guide

10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas

BCOP Board Certified Oncology Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & BCOP Exam Foundations

1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy

2 Chapter 2: Cancer Biology & Pathophysiology

2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion

3 Chapter 3: Genomic Biomarkers & Molecular Targets

3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6

4 Chapter 4: Diagnostics, Staging & Clinical Assessment

4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention

5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens

5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins

6 Chapter 6: Targeted Small-Molecule Therapies

6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways

7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy

7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics

8 Chapter 8: Breast & Gynecologic Malignancies

8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies

9 Chapter 9: Thoracic & Skin Malignancies

9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers

10 Chapter 10: Gastrointestinal & Genitourinary Malignancies

10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas

11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma

11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP

12 Chapter 12: Lymphomas & Stem Cell Transplantation

12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease

13 Chapter 13: Supportive Care & Toxicity Management

13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes

14 Chapter 14: Hazardous Drug Handling & Compounding Safety

14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response

15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification

15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination

16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation

16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal

17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education

17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology

10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas

Key Takeaways Explain This Topic AI

Metastatic castration-sensitive prostate cancer (mCSPC) standard of care has transitioned from ADT monotherapy to intensified doublet therapy (ADT plus androgen receptor pathway inhibitor [ARPI] or docetaxel) or triplet therapy (ADT plus docetaxel plus darolutamide via ARASENS or abiraterone via PEACE-1) for high-volume/high-risk disease.

Precision mCRPC therapeutics require somatic/germline testing for homologous recombination repair (HRR) gene mutations (olaparib, rucaparib, talazoparib, niraparib, demonstrating profound efficacy in BRCA2 alterations) and PSMA-PET imaging for lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617 radioligand therapy).

Clear cell renal cell carcinoma (ccRCC) frontline standard of care is risk-stratified using the IMDC criteria: intermediate/poor-risk disease is treated with dual checkpoint blockade (nivolumab plus ipilimumab) or IO-TKI combinations (pembrolizumab plus axitinib/lenvatinib, nivolumab plus cabozantinib), whereas adjuvant pembrolizumab for 1 year (KEYNOTE-564) provides a proven overall survival benefit in resected high-risk disease.

Belzutifan (Welireg), an oral HIF-2alpha inhibitor, is approved for advanced ccRCC post-PD-1 and VEGFR TKIs (LITESPARK-005), requiring clinical pharmacist monitoring for signature on-target toxicities including severe anemia (erythropoietin depletion) and hypoxia.

Locally advanced and metastatic urothelial carcinoma has been fundamentally revolutionized by the frontline combination of enfortumab vedotin plus pembrolizumab (EV-302 / KEYNOTE-A39), which virtually doubled median overall survival (31.5 vs 16.1 months; HR 0.47) over historic platinum-based chemotherapy, accompanied by signature EV toxicities including severe peripheral neuropathy, cutaneous toxicities (SJS/TEN risk), and severe hyperglycemia.

Last updated: August 2026

10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas

Genitourinary (GU) malignancies encompass a diverse group of solid tumors originating from the prostate, kidneys, and urothelial tract. Over the last decade, GU oncology has undergone a monumental paradigm shift driven by hormonal intensification, immunotherapeutic checkpoint inhibition, antibody-drug conjugates (ADCs), hypoxia-inducible factor (HIF) targeting, and precision radioligand therapeutics.

Board-certified oncology pharmacists play an essential role in navigating androgen deprivation therapy (ADT) and Androgen Receptor Pathway Inhibitor (ARPI) toxicities (e.g., secondary hyperaldosteronism with abiraterone, metabolic/bone mineral density decline), balancing dual immunotherapy vs. IO-TKI combinations in renal cell carcinoma, managing unique ADC adverse effects (e.g., life-threatening cutaneous reactions and hyperglycemia with enfortumab vedotin), and monitoring radiopharmaceutical logistics.

1. Prostate Cancer: Disease Continuum and Androgen Deprivation

Prostate cancer progresses through defined clinical states along the androgen axis: Localized -> Biochemical Recurrence -> Non-Metastatic Castration-Resistant (nmCRPC) -> Metastatic Castration-Sensitive (mCSPC) -> Metastatic Castration-Resistant Prostate Cancer (mCRPC). +-----------------------------------------------------------------------------+

  • | PROSTATE CANCER CLINICAL CONTINUUM |
  • | |
  • | LOCALIZED PROSTATE CANCER: |
  • | - Very Low / Low Risk: Active Surveillance |
  • | - Intermediate / High Risk: Radical Prostatectomy OR Definitive RT + ADT |
  • | |
  • | METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (mCSPC): |
  • | - Standard: ADT Backbone + INTENSIFICATION (Doublet or Triplet) |
  • | - Avoid ADT monotherapy alone (obsolete standard) |
  • | |
  • | NON-METASTATIC CASTRATION-RESISTANT (nmCRPC): |
  • | - Castrate serum testosterone (<50 ng/dL), rising PSA, NO distant mets on |
  • | conventional CT/bone scan, PSA Doubling Time (PSADT) <= 10 months |
  • | - Standard: ADT + APALUTAMIDE / ENZALUTAMIDE / DAROLUTAMIDE |
  • | |
  • | METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC): |
  • | - ARPIs (Abiraterone, Enzalutamide) | Taxanes (Docetaxel, Cabazitaxel) |
  • | - PARP Inhibitors (Olaparib, Talazoparib, Rucaparib, Niraparib for HRRm) |
  • | - Radioligand Therapy: Lutetium-177 PSMA-617 (VISION) |
  • | - Bone-Targeted Alpha Emitter: Radium-223 (ALSYMPCA) |
  • | - Cellular Immunotherapy: Sipuleucel-T (IMPACT) |
  • +-----------------------------------------------------------------------------+
  • Androgen Deprivation Therapy (ADT) Pharmacology

Castration is defined as achieving and maintaining serum testosterone <50 ng/dL (optimally <20 ng/dL).

LHRH (GnRH) Agonists (Leuprolide, Goserelin, Triptorelin): Bind pituitary LHRH receptors, causing an initial surge in LH and FSH, producing a transient testosterone flare (Days 1–14). This flare can cause spinal cord compression, urinary obstruction, or bone pain in patients with bulky metastases. Clinical Pearl: Co-administer a first-generation antiandrogen (e.g., Bicalutamide 50 mg PO daily ) starting >=7 days prior to or concurrently with the LHRH agonist for 2–4 weeks to block the receptor during the flare.

LHRH (GnRH) Antagonists (Degarelix SQ monthly, Relugolix 120 mg PO daily): Competitively block pituitary GnRH receptors, inducing immediate LH/FSH and testosterone suppression without testosterone flare . Degarelix and relugolix achieve faster testosterone reduction and carry a lower risk of major adverse cardiovascular events (MACE) compared to LHRH agonists (HERO trial).

Adverse Effects of Long-Term ADT: Vasomotor hot flashes, loss of libido, sarcopenia, fatigue, metabolic syndrome (insulin resistance, dyslipidemia), osteopenia/osteoporosis (mandates baseline DEXA scan, calcium 1000–1200 mg/day, Vitamin D3 800–2000 IU/day, and bone antiresorptive agents: zoledronic acid or denosumab), and cardiovascular morbidity.

2. Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

ADT alone is no longer an acceptable standard for mCSPC. Treatment must be intensified with doublet or triplet systemic therapy. +-----------------------------------------------------------------------------+

  • | mCSPC INTENSIFICATION TREATMENT ALGORITHM |
  • | |
  • | [CONFIRMED METASTATIC CSPC / HSPC] |
  • | | |
  • | +---------------------------+---------------------------+ |
  • | | | |
  • | v v |
  • | [HIGH-VOLUME / HIGH-RISK DISEASE] [LOW-VOLUME DISEASE] |
  • | (CHAARTED: >=4 bone mets with >=1 (Oligometastatic / |
  • | beyond axial skeleton, and/or visceral) Low burden bone mets) |
  • | | | |
  • | v v |
  • | [TRIPLET THERAPY (Preferred Category 1)] [DOUBLET THERAPY] |
  • | 1. ADT + DOCETAXEL (6 cycles) + 1. ADT + ENZALUTAMIDE |
  • | DAROLUTAMIDE (ARASENS Trial: (ARCHES / ENZAMET) |
  • | 32% reduction in risk of death; HR 0.68) 2. ADT + APALUTAMIDE |
  • | 2. ADT + DOCETAXEL (6 cycles) + (TITAN Trial) |
  • | ABIRATERONE + PREDNISONE 3. ADT + ABIRATERONE + |
  • | (PEACE-1 Trial: OS HR 0.75) PREDNISONE (LATITUDE) |
  • | 4. ADT + Radiation to |
  • | [DOUBLET ALTERNATIVE (Frail / Taxane Infit)] Primary (STAMPEDE) |
  • | - ADT + Abiraterone / Enzalutamide / Apalutamide |
  • +-----------------------------------------------------------------------------+
  • 3. Metastatic Castration-Resistant Prostate Cancer (mCRPC)

In the mCRPC setting, castration therapy with ADT (LHRH agonist/antagonist) must be continued indefinitely to maintain castrate testosterone levels (<50 ng/dL) regardless of subsequent systemic therapy lines. +-----------------------------------------------------------------------------+

  • | mCRPC PRECISION THERAPEUTIC OPTIONS |
  • | |
  • | 1. ANDROGEN RECEPTOR PATHWAY INHIBITORS (ARPIs): |
  • | - ABIRATERONE ACETATE (1000 mg PO Daily on EMPTY STOMACH) + |
  • | PREDNISONE (5 mg PO BID) [COU-AA-301 / 302 Trials] |
  • | * CYP17 (17alpha-hydroxylase & C17,20-lyase) inhibitor |
  • | * Toxicities: Secondary Hyperaldosteronism (Hypertension, |
  • | Hypokalemia, Fluid Retention) -> Prevented by co-administered |
  • | prednisone; Hepatotoxicity (monitor AST/ALT/Bilirubin). |
  • | - ENZALUTAMIDE (160 mg PO Daily with or without food) [AFFIRM / PREVAIL]|
  • | * AR signaling inhibitor (blocks binding, nuclear translocation, DNA)|
  • | * Toxicities: Fatigue (35%), Falls, Seizure risk (0.9%), Drug |
  • | Interactions (Strong CYP3A4, moderate CYP2C9/2C19 inducer). |
  • | |
  • | 2. TAXANE CHEMOTHERAPY: |
  • | - DOCETAXEL (75 mg/m2 IV Q3W + Prednisone 5 mg BID) [TAX 327 Trial] |
  • | - CABAZITAXEL (20-25 mg/m2 IV Q3W + Prednisone 5 mg Daily) [TROPIC/CARD|
  • | * Overcomes docetaxel resistance (poor substrate for P-gp efflux) |
  • | * High myelosuppression -> Mandatory primary G-CSF prophylaxis. |
  • | |
  • | 3. PARP INHIBITORS IN HOMOLOGOUS RECOMBINATION REPAIR (HRR) MUTATIONS: |
  • | - OLAPARIB (300 mg PO BID) [PROfound Trial: BRCA1, BRCA2, ATM, etc.] |
  • | - RUCAPARIB (600 mg PO BID) [TRITON3 Trial: BRCA1/2, ATM] |
  • | - TALAZOPARIB + ENZALUTAMIDE [TALAPRO-2: HRR-mutated mCRPC] |
  • | - NIRAPARIB + ABIRATERONE / PREDNISONE [MAGNITUDE Trial: BRCA1/2-mut] |
  • | * Synthetic lethality in homologous recombination deficiency; |
  • | profound benefit in BRCA2 alterations. Monitor Anemia & Platelets. |
  • | |
  • | 4. RADIOPHARMACEUTICALS: |
  • | - LUTETIUM-177 VIPIVOTIDE TETRAXETAN (177Lu-PSMA-617) [VISION Trial]: |
  • | * 7.4 GBq (200 mCi) IV Q6W for up to 6 cycles |
  • | * Beta-emitting radioligand targeting PSMA on prostate cancer cells |
  • | * Requires PSMA-PET (68Ga-PSMA-11 or 18F-DCFPyL) positivity |
  • | * Toxicities: Myelosuppression (anemia, thrombocytopenia), Xerostomia|
  • | (dry mouth in 39%), renal impairment. |
  • | - RADIUM-223 DICHLORIDE [ALSYMPCA Trial]: |
  • | * Alpha-emitting calcium mimetic targeting bone osteoblastic turnover|
  • | * Indicated for symptomatic bone metastases WITHOUT visceral disease |
  • | * DO NOT COMBINE WITH ABIRATERONE (increased bone fractures/death) |
  • +-----------------------------------------------------------------------------+
  • 4. Renal Cell Carcinoma (RCC): Clear Cell vs. Non-Clear Cell

Clear Cell Renal Cell Carcinoma (ccRCC, ~75–80% of RCC) is driven by loss or inactivation of the Von Hippel-Lindau ( VHL ) tumor suppressor gene on chromosome 3p. Loss of VHL prevents ubiquitin-mediated degradation of HIF-1alpha and HIF-2alpha , leading to constitutive transcription of VEGF, PDGF, and TGF-alpha, producing hypervascular tumors.

IMDC (Heng) Risk Stratification for Metastatic ccRCC

Systemic therapy selection is guided by the International Metastatic RCC Database Consortium (IMDC) risk model, based on 6 clinical factors:

  • Karnofsky Performance Status (KPS) < 80%
  • Time from initial diagnosis to systemic therapy < 1 year
  • Hemoglobin < Lower Limit of Normal (LLN)
  • Corrected Serum Calcium > Upper Limit of Normal (ULN)
  • Absolute Neutrophil Count > ULN
  • Platelet Count > ULN

Favorable Risk (0 factors): Median OS ~43–50 months.

Intermediate Risk (1–2 factors): Median OS ~22–27 months.

Poor Risk (3–6 factors): Median OS ~8–12 months. +-----------------------------------------------------------------------------+

  • | METASTATIC ccRCC FRONTLINE TREATMENT MATRIX |
  • | |
  • | [INTERMEDIATE / POOR RISK IMDC (Category 1 Options)] |
  • | 1. DUAL CHECKPOINT BLOCKADE: |
  • | * NIVOLUMAB (3 mg/kg) + IPILIMUMAB (1 mg/kg) IV Q3W x 4 doses -> |
  • | Nivolumab maintenance 240 mg Q2W / 480 mg Q4W [CheckMate 214] |
  • | * High Complete Response rate (~10-12%), durable OS plateau |
  • | 2. IO + TKI COMBINATIONS: |
  • | * PEMBROLIZUMAB (200 mg Q3W) + AXITINIB (5 mg PO BID) [KEYNOTE-426] |
  • | * NIVOLUMAB (240 mg Q2W) + CABOZANTINIB (40 mg PO Daily) [CheckMate 9ER]|
  • | * PEMBROLIZUMAB (200 mg Q3W) + LENVATINIB (20 mg PO Daily) [CLEAR] |
  • | (CLEAR Trial: Highest median PFS 23.9 mo and ORR 71%) |
  • | |
  • | [FAVORABLE RISK IMDC] |
  • | - Preferred: IO + TKI Combination (Pembrolizumab + Axitinib / Lenvatinib; |
  • | Nivolumab + Cabozantinib) |
  • | - Alternative: Active Surveillance (indolent disease) OR Single-Agent TKI |
  • | |
  • | [ADJUVANT ccRCC THERAPY (KEYNOTE-564)] |
  • | - High-Risk Resected ccRCC (pT2 high-grade, pT3-T4, pN+, or M1 NED) |
  • | - PEMBROLIZUMAB 200 mg Q3W (or 400 mg Q6W) x 1 YEAR |
  • | - Landmark Overall Survival Benefit: 38% reduction in death (HR 0.62) |
  • +-----------------------------------------------------------------------------+
  • Belzutifan (Welireg): Breakthrough HIF-2alpha Inhibitor

Mechanism of Action: First-in-class small molecule that selectively binds to the PAS-B domain of HIF-2alpha , blocking its heterodimerization with HIF-1beta (ARNT) and inhibiting downstream oncogenic transcription of VEGF, cyclin D1, and erythropoietin.

Indications:

Advanced clear cell RCC following prior PD-1/PD-L1 checkpoint inhibitor and VEGF-TKI therapy (Phase 3 LITESPARK-005 Trial ).

Adult patients with Von Hippel-Lindau (VHL) disease who require therapy for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors.

Dosing: 120 mg PO once daily continuously with or without food.

Signature Class Toxicities & Interception:

Severe Anemia (Boxed Warning / Class Effect in >80–90%; Grade 3 in ~30%): Because HIF-2alpha regulates physiological renal erythropoietin (EPO) production, belzutifan directly suppresses erythropoiesis. Monitoring: Check baseline and periodic hemoglobin. Manage with Erythropoiesis-Stimulating Agents (ESAs: epoetin alfa, darbepoetin) and blood transfusions. Withhold for Hb <8.0 g/dL.

Severe Hypoxia (Class Effect in 10–15%): Monitor oxygen saturation by pulse oximetry at baseline, periodically, and with any exertional dyspnea. Withhold for SpO2 <88% or severe exercise-induced desaturation; administer supplemental oxygen.

5. Urothelial Carcinoma: The Transformed Paradigm

Urothelial carcinoma comprises malignancies of the urinary bladder (~90%), renal pelvis, ureters, and urethra. +-----------------------------------------------------------------------------+

  • | UROTHELIAL CARCINOMA CLINICAL PATHWAYS |
  • | |
  • | NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC: Ta, T1, CIS): |
  • | - Transurethral Resection of Bladder Tumor (TURBT) |
  • | - Followed by Intravesical BCG (Bacillus Calmette-Guerin) |
  • | * Induction: 6 weekly instillations |
  • | * Maintenance: 3 weekly instillations at 3, 6, 12, 18, 24, 30, 36 months|
  • | - BCG-Unresponsive NMIBC: Intravesical Nadofaragene firadenovec, |
  • | Nogapendekin alfa inbakicept (IL-15 superagonist) + BCG, or Pembrolizumab|
  • | |
  • | MUSCLE-INVASIVE BLADDER CANCER (MIBC: cT2-T4a N0 M0): |
  • | - Standard: NEOADJUVANT CISPLATIN CHEMOTHERAPY (ddMVAC x 4c with G-CSF |
  • | OR Gemcitabine + Cisplatin x 4c) -> RADICAL CYSTECTOMY + PELVIC LND |
  • | - Adjuvant Immunotherapy (CheckMate 274 Trial): |
  • | * High-Risk Resected MIBC (ypT2-ypT4a or ypN+ post-neoadjuvant chemo; |
  • | or pT3-pT4a / pN+ without prior neoadjuvant cisplatin) |
  • | * ADJUVANT NIVOLUMAB 240 mg Q2W / 480 mg Q4W x 1 YEAR (DFS HR 0.70) |
  • | |
  • | METASTATIC UROTHELIAL CARCINOMA (mUC) - THE EV-302 REVOLUTION: |
  • | - UNIVERSAL FRONTLINE STANDARD OF CARE: |
  • | * ENFORTUMAB VEDOTIN (1.25 mg/kg D1, 8) + PEMBROLIZUMAB (200 mg D1) Q21D|
  • | * EV-302 / KEYNOTE-A39 Trial: Doubled mOS (31.5 vs 16.1 mo; HR 0.47) |
  • | and mPFS (12.5 vs 6.3 mo; HR 0.45) over standard Platinum Doublet! |
  • | * Replaces Gemcitabine + Cisplatin/Carboplatin as Frontline Standard. |
  • | |
  • | - Alternative Frontline Options (EV Unfit / Ineligible): |
  • | * Gemcitabine + Cisplatin + Nivolumab -> Nivolumab Maint (CheckMate 901)|
  • | * Gemcitabine + Cisplatin/Carboplatin x 4-6c -> Consolidation Avelumab |
  • | Maintenance (JAVELIN Bladder 100 Trial: mOS 23.8 vs 15.0 mo, HR 0.69) |
  • | |
  • | - Targeted Second-Line Therapeutics: |
  • | * ERDAFITINIB (FGFR1-4 TKI) for susceptible FGFR3/2 alterations (THOR) |
  • | * SACITUZUMAB GOVITECAN (Trop-2 directed ADC with SN-38 payload) |
  • +-----------------------------------------------------------------------------+
  • Enfortumab Vedotin (EV): Mechanism and Toxicity Mitigation

Target & Structure: Fully human monoclonal antibody directed against Nectin-4 (cell adhesion molecule highly expressed on >90% of urothelial carcinomas), conjugated via a protease-cleavable valine-citrulline linker to the microtubule-disrupting agent Monomethyl Auristatin E (MMAE) .

Signature Boxed Warnings & Class Toxicities:

Severe Cutaneous Adverse Reactions (Boxed Warning): Severe rash, maculopapular eruptions, Stevens-Johnson syndrome (SJS), and Toxic Epidermal Necrolysis (TEN). Monitor closely; withhold for Grade 2 worsening rash; permanently discontinue for suspected SJS/TEN or exfoliative dermatitis .

Hyperglycemia & Diabetic Ketoacidosis (Boxed Warning): EV triggers severe, life-threatening hyperglycemia even in patients with normal baseline glucose. Monitor blood glucose closely. Withhold EV if blood glucose >250 mg/dL until controlled.

Peripheral Neuropathy (Sensory and Motor in ~50%): Axonal polyneuropathy from MMAE tubulin inhibition. Dose reductions (1.0 mg/kg -> 0.75 mg/kg -> 0.5 mg/kg) or treatment holds required for Grade >=2 neuropathy.

Ocular Disorders: Keratitis, dry eye symptoms; prophylactic artificial tears and ophthalmologic evaluation for persistent visual changes.

Erdafitinib (Balversa) in FGFR-Altered Urothelial Carcinoma

Indication: Adult patients with susceptible FGFR3 genetic alterations (mutations or fusions) whose mUC progressed on prior systemic therapy ( THOR Trial: OS HR 0.64 vs chemotherapy ).

Dosing & Dose Titration: Initial dose is 8 mg PO once daily . Assess serum phosphate levels at Day 14 to 21 . If serum phosphate is <9.0 mg/dL and there are no drug-related toxicities, escalate dose to 9 mg PO once daily .

Key Toxicities: Hyperphosphatemia, central serous retinopathy (mandatory baseline/periodic visual field and optical coherence tomography exams), onycholysis, and severe dry mouth / stomatitis.

Master Summary Matrix: Genitourinary Landmark Practice Milestones

Disease Setting Primary Landmark Trial(s) Standard Regimen Critical Pharmacist Monitoring Points

mCSPC (High-Volume) ARASENS ; PEACE-1 ADT + Docetaxel (6c) + Darolutamide OR Abiraterone/Prednisone Darolutamide has lowest CNS penetration; Abiraterone requires co-administered prednisone.

mCRPC (Post-ARPI) TAX 327 ; TROPIC / CARD Docetaxel 75 mg/m2 Q3W OR Cabazitaxel 20–25 mg/m2 Q3W Primary G-CSF for cabazitaxel; monitor docetaxel fluid retention (dexamethasone premed).

mCRPC (HRR / BRCA+) PROfound ; TALAPRO-2 Olaparib 300 mg BID OR Talazoparib + Enzalutamide NGS testing for BRCA1/2/ATM ; monitor hematologic toxicity (anemia, thrombocytopenia).

mCRPC (PSMA+) VISION Lutetium-177 vipivotide tetraxetan (7.4 GBq Q6W x 6c) Confirmed PSMA-PET positivity; monitor for myelosuppression and xerostomia.

mCRPC (Bone Only) ALSYMPCA Radium-223 dichloride IV monthly x 6 injections Alpha-emitter for symptomatic bone mets; strictly contraindicated with abiraterone.

ccRCC (Int/Poor Risk) CheckMate 214 ; CLEAR / 9ER Nivolumab + Ipilimumab OR IO + TKI (Pembrolizumab + Lenvatinib) Dual IO achieves durable complete responses; IO+TKI provides high ORR and rapid tumor shrinkage.

ccRCC (High-Risk Resected) KEYNOTE-564 Adjuvant Pembrolizumab 200 mg Q3W x 1 year Demonstrated landmark OS benefit (HR 0.62); screen for immune-mediated endocrinopathies.

ccRCC (Refractory) LITESPARK-005 Belzutifan 120 mg PO once daily HIF-2alpha inhibitor; monitor hemoglobin (severe anemia from EPO block) and oxygen saturation.

mUC (Frontline Standard) EV-302 / KEYNOTE-A39 Enfortumab Vedotin 1.25 mg/kg (D1, 8) + Pembrolizumab Q21D Landmark OS doubling (mOS 31.5 mo); monitor for severe rash/SJS, hyperglycemia, and neuropathy.

mUC (Consolidation) JAVELIN Bladder 100 Avelumab 10 mg/kg (or 800 mg) Q2W post-platinum Administer within 4–10 weeks post-platinum in patients with stable disease or objective response.

mUC (FGFR3 Altered) THOR Erdafitinib 8 mg daily -> Up-titrate to 9 mg if phosphate <9.0 mg/dL Serum phosphate check Day 14–21; mandatory baseline and regular ophthalmologic exams for CSR.